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Background: Our study aimed to determine the burden of illness in dystrophinopathy type Duchenne (DMD) and
Becker (BMD), both leading to progressive disability, reduced working capacity and high health care utilization.
Methods: A micro-costing method was used to examine the direct, indirect and informal care costs measuring
the economic burden of DMD in comparison to BMD on patients, relatives, payers and society in Germany and to
determine the health care burden of these diseases. Standardized questionnaires were developed based on
predefined structured interview guidelines to obtain data directly from patients and caregivers using the German
dystrophinopathy patient registry. The health-related quality of life (HRQOL) was analyzed using PedsQL™
Measurement Model.
Results: In total, 363 patients with genetically confirmed dystrophinopathies were enrolled. Estimated annual disease
burden including direct medical/non-medical, indirect and informal care costs of DMD added up to € 78,913 while
total costs in BMD were € 39,060. Informal care costs, indirect costs caused by loss of productivity and absenteeism of
patients and caregivers as well as medical costs of rehabilitation services and medical aids were identified as the most
important cost drivers. Total costs notably increased with disease progression and were consistent with the clinical
severity; however, patients’ HRQOL declined with disease progression.
Conclusion: In conclusion, early assessments of economic aspects and the disease burden are essential to gain
extensive knowledge of a distinct disease and above all play an important role in funding drug development
programs for rare diseases. Therefore, our results may help to accelerate payer negotiations such as the pricing
and reimbursement of new therapies, and will hopefully contribute to facilitating the efficient translation of
innovations from clinical research over marketing authorization to patient access to a causative treatment.
Keywords: Duchenne muscular dystrophy, Becker muscular dystrophy, Direct costs, Indirect costs, Informal
care costs, Cost of illness (COI), Burden of illness, Health care burden, Health-related quality of life (HRQOL),
Socio-economic evaluationBackground
Duchenne muscular dystrophy (DMD) is a hereditary
X-linked neuromuscular disorder due to mutations in
the dystrophin gene with a worldwide incidence of appro-
ximately 1:5,000 male newborns [1,2] leading to progres-
sive muscle atrophy and weakness. First symptoms are* Correspondence: maggie.walter@lrz.uni-muenchen.de
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article, unless otherwise stated.usually noted between the age of three to five, while loss
of ambulation occurs around age 12, along with scoliosis,
contractures, respiratory and cardiac impairment which
require early ventilatory support and drug treatment. Life
expectancy is reduced to 30-40 years of age although
multidisciplinary symptomatic and surgical treatment
has considerably improved survival within the last two
decades [3-5].
Becker muscular dystrophy (BMD) represents a milder
allelic form of dystrophinopathy, with a broader variabilityCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Definition of patient/parent self-evaluated
clinical severity stages
Stage Clinical characteristics of DMD and BMD boys/men
I Early ambulatory with mild impairment: Gowers’ maneuver,
waddling gait, walking on toes, problems with climbing stairs.
II Late ambulatory with high impairment: Walking becomes
increasingly difficult, more problems climbing stairs and getting
up from the floor, part-time wheelchair use.
III Early non-ambulatory: Loss of ambulation, active manual
wheelchair use possible, independent standing and sitting still
possible for some time.
IV Late non-ambulatory: Independent electric wheelchair use but
decline of upper limb function and ability to sit independently.
V Non-ambulatory with confinement to bed: Loss of independent
mobility, hand function preserved on a low level.
According to self-evaluated clinical symptoms and motor function DMD and
BMD patients were divided into corresponding subgroups to reveal potential
correlations between these functional stages and the burden of illness.
Modification after Bushby K et al., The Lancet Neurology, 2010 [3].
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slower progression with an estimated incidence of
1:20,000 [6,7]. However, only symptomatic treatment is
available for slowing down disease progression in both
forms of the disease. Therefore, Duchenne and Becker
muscular dystrophy inevitably result in reduced working
capacity and costly health care utilization for patients and
caregivers. Until now, the burden of DMD and BMD
regarding patients, family caregivers, health care systems
and society has scarcely been investigated [8]. Our study
aimed to assess the cost of illness (COI) and health-
related quality of life (HRQOL) of both DMD and BMD
patients in Germany, to forecast and model the burden of
illness from a health economic and clinical perspective.
Methods
We performed a cross-sectional study approaching all
male patients with a confirmed genetic diagnosis of
DMD or BMD (n = 733) via the German dystrophinopa-
thy patient registry (www.dmd-register.de) and/or their
caring relatives (hereafter referred to as “parents”), re-
spectively, to evaluate the burden of dystrophinopathy.
The dystrophinopathy patient registry was established
within the network of excellence TREAT-NMD (www.
treat-nmd.eu) in 2008 as described elsewhere [9]. Stan-
dardized questionnaires adapted to either DMD or
BMD were developed in close cooperation with clinicians,
economists and representatives of German patient organi-
zations, consisting of several sections addressing patients’
and parents’ socio-demographic data, health status, use
of resources over a specific time period and the current
or previous employment of patients and parents. The
PedsQL™ Measurement Model, module for neuromus-
cular disorders, German version 3.0, was applied to
analyze the quality of life. Following a pretesting phase
with personal interviews with patients and caregivers,
the survey started in June 2013 and was closed in
December 2013. Questionnaires were sent out to pa-
tients and parents either by mail or online and were
answered either by adolescent/adult patients aged 16
and older or by their parents (in the case of younger
patients or patients dependent on part- or fulltime care).
Based on the subjective evaluation of patients/parents,
DMD and BMD patients were classified into disease sever-
ity stages mirroring disease progression and motor func-
tion (Table 1). Thereby the differences between DMD and
BMD, and within their disease progression could be
analyzed. Ethical approval was obtained from the ethics
board of the Ludwig-Maximilians-University of Munich;
and patients/legal guardians and parents gave their
written consent to participate in the study.
A micro-costing method was used to retrospectively
examine the direct, indirect and informal care costs from a
societal perspective. To evaluate the direct COI - includinge.g. costs of hospitalization, drug treatment, rehabilitation
services such as physiotherapy and occupational therapy -
the use of resources was identified and monetarily assessed
using the official German price lists of 2013 [10,11].
Incurred costs of health care services were extrapolated to
one year, assuming constant use of resources. Cost drivers
as constructional adaptions of the environment as well as
advocate support were estimated as cumulative per-patient
mean costs that incurred up to the date the questionnaire
was completed. In addition the costs of medical aids and
respiratory management were estimated as stage-specific
mean costs. By extrapolating the mean duration of DMD
and BMD stages within our patient cohort based on age at
diagnosis and age and disease stage at the time of the study
participation, the annual costs were estimated for these
cost categories, respectively. For assessing costs of informal
care, only the care effort of non-working parents was
calculated in hours per day preventing an overestimation
of indirect and informal care costs by double counting
working parents’ care time and their loss of productivity.
We developed a formula to calculate the economic loss of
productivity caused by absenteeism, invalidity or changes
in the work situation of patients and parents by analyzing
patients and parents indirect COI (see Additional file 1).
Compared to the human capital approach, the developed
formula delivers a more precise description of the real-life
situation by taking factors such as short-time absenteeism
or the actual wage levels into account [12]. Differences in
costs and HRQOL between DMD and BMD were analyzed
using the Mann-Whitney-U-test within the SPSS® software
package; results are presented in Euro for 2013.
Results
Patient cohort characterization
363 patient/parent pairs were included in the analysis
(response rate 50%: 363/733; DMD 43% = 248/571, BMD
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clinical severity stages IV, II and I in contrast to the
majority of BMD patients who were in stages II and I
(none was in stage V). The age of the DMD patients
ranged from 1 to 42 years (median 11y), while BMD pa-
tients were between 2.5 and 62 years old (median 26.5y);
however, median age increased with clinical severity (ex-
cept for BMD stage III; Table 2).
The assessment of the family status of the patients
revealed that most DMD patients (96%) were unmarried
whereas in the BMD population nearly 50% were mar-
ried or in a partnership. The percentage of DMD and
BMD parents who were married/in a partnership were
87% and 74%, respectively (Table 3). Health costs were
covered by a statutory health insurance in the majority
of patients (DMD 91%; BMD 87%), only 9%/13% of
DMD/BMD patients had private health insurance (data
not shown), which is in line with the ratio within the
German population [13]. The German health care system
provides long-term nursing care insurance with three
different levels of financial support, depending on the
patients’ impairment and their need of nursing services
[14]. Within the analyzed DMD cohort, 30% of patients
were not yet classified into care levels. In contrast, 17%
of patients were classified into care level 1 (median age
8y), 23% into care level 2 (median age 13y) and 31% into
the most severe care level 3 (median age 20y). Within
the BMD population, 76% of patients did not qualify for
any of the care levels, 14% were in care level 1 (median
age 35.5y) and 4%/5% were classified into care levels 2 and
3 (median age 41/50y; data not shown).
Estimation of direct medical cost of illness
The consumption of direct medical resources was notably
higher in DMD than in BMD patients. The most striking
differences were seen regarding the demand of rehabilita-
tion services (e.g. physiotherapy, occupational therapy and
logopedics), drug treatment, use of medical aids and in-
and outpatient medical consultations. Additionally, DMD
patients required health care resources much earlier thanTable 2 Response rate and age distribution within the analyz
DMD
Total I II III
Response rate
Absolute numbers 248/571 49 70 11
Ratio of total DMD/BMD [%] 43 20 28 4
Respondents patients/parents [%] 10/90
Age of patients
Min. [years] 1 1 3 10
Max. [years] 42 14 42 23
Median [years] 11 4 7.5 13
Response rates and age distribution were differentiated based on clinical severity sBMD patients; e.g. DMD patients needed in-patient treat-
ments within a median average age of 14 years, while
BMD patients were already 40 years of age. Moreover,
osteoporosis was more frequently seen in DMD than in
BMD, occurring earlier in DMD and requiring medical
treatment (12% of DMD patients, median age 20 y, 39%
with drug treatment; vs. 3% of BMD patients, median age
44y, none with drug treatment; data not shown). More
than three quarters of DMD (84.9%) and more than half
of BMD patients (59.6%) stated that they need medical
aids. Within the investigated patient cohort, DMD boys
became full-time wheelchair bound at a median age of
15 years compared to BMD at a median age of 40 years. In
contrast, an assessment of the ongoing need for respira-
tory management showed that 3% of DMD (each 50% in
stages IV and V; aged 2 to 25 y, median 21y) and 2.7% of
BMD patients (67%/33% in stage II/IV; aged 7 to 59 y,
median 40 y) used an invasive or non-invasive ventilatory
device. Overall, DMD patients exhibited a more severe
morbidity along with a higher need for direct medical
care (Figure 1).
Based on these differences, the mean direct annual COI
of DMD was estimated at € 19,346 and thus 3.8 times
higher compared to € 5,140 in BMD (Tables 4 and 5).
Main direct medical cost drivers were especially costs of
medical aids in DMD (13% of total COI), costs of rehabi-
litation services (DMD/BMD 6% of total COI) and costs
of inpatient medical treatment in BMD (3% of total COI).
A detailed comparison of direct medical costs between
DMD and BMD revealed different patterns of evolving
costs through the disease stages, especially a decline of
outpatient medical costs and costs of rehabilitation pro-
grams from the time-point at which the patients lost their
ability to walk, while inpatient medical costs, drug treat-
ment costs, costs of medical aids and respiratory therapy
jumped up with disease progression. DMD costs of res-
piratory management increased to € 2,771 in stage V
(mean: € 875), compared to € 234 in BMD stage IV (mean
€ 83). The costs of medical aids for DMD patients
(€ 10,209) were significantly higher compared to BMDed patient cohort
BMD
IV V Total I II III IV V
92 26 115/162 42 55 8 10 0
37 11 71 37 48 7 9 0
68/32
1 11 2.5 2.5 7 7 21 -
31 40 62 52 59 41 62 -
16 22.5 26.5 16 33 30 51 -
tages. Because of rounding, percentage might not add up to exactly 100%.
Table 3 Family status, education and employment status
within the analyzed patient cohort
DMD BMD
Patients Parents Patients Parents
Family status
[%]
Widowed 0 2 0 0
Divorced 0 5 4 9
Married 4 83 36 71
In a
partnership
0 4 13 3
Unmarried 96 6 47 17
Education [%] No
qualification
20 2 0 3
School 74 78 82 82
University
studies




39 89 77 82
Employment
status [%]
Non-working 49 8 32 18
Currently
working
Self-employed 2 7 8 11
Employed 37 56 49 67
Quit working
life
12 29 12 4
In stage I - 17 0 0
In stage II 0 52 63 50
In stage III 25 15 13 0
In stage IV 50 13 25 50




6 38 25 12
In stage I - 10 22 71
In stage II 11 55 67 14
In stage III 11 13 11 14
In stage IV 67 19 0 0
In stage V 11 3 - -
Gross salary
per year [€]
Mean 11,405 24,168 35,871 27,414
Stage I - 25,971 45,120 29,937
Stage II 22,200 25,140 33,377 22,071
Stage III 2,400 30,722 33,720 40,200
Stage IV 13,572 22,976 32,644 28,054
Stage V 6,712 17,745 - -
These demographic parameters were assessed to serve as basis for indirect
cost calculation. Assessment was differentiated between patients and parents
in consideration of patients’ clinical severity stages. Because of rounding,
percentage might not add up to exactly 100%.
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in stage V), whereas BMD mean costs of medical aids
peaked out in stage III on a considerably lower level(€ 3,611). Major cost drivers were aids supporting mobil-
ity such as wheelchairs, representing not only the most
frequently used aids but also the most expensive devices
(as well as other home care tools).
Estimation of direct non-medical cost of illness
In contrast to direct medical costs, total direct costs
additionally take non-medical cost factors into account.
Both, direct medical and non-medical COI, increased
with disease severity with a leap between DMD stage IV
and V and BMD stage III and IV. Considerably lower
costs of BMD compared to DMD patients were mainly
seen in stages I to III. Regarding direct non-medical
costs, main cost drivers - apart from informal care costs
- were the costs for the housing situation, e.g. caused by
a mobile nursing service. These costs were twice as high
in DMD as compared to BMD; however, there was a
notable escalation with disease progression, resulting in
higher mean costs of BMD patients in stage IV com-
pared to DMD patients in stage V. The second important
cost driver of non-medical direct costs were expenses due
to the progressing physical impairment, e.g. constructional
adaptions of the house (DMD 4%; BMD 2% of total COI)
and the car (DMD: 1%; BMD 2% of total COI). House
adaption costs of both DMD and BMD peaked in the
second last stage (DMD € 8,499; BMD € 4,369). Add-
itionally expenses for car adaptions peaked in stage III
in DMD and BMD; however, BMD costs were nearly
three times as high compared to DMD (DMD € 2,609;
BMD € 7,626).
Moreover, informal care costs turned out to be the
most important cost driver of direct resource consumption,
mainly in severe dystrophinopathies, and also had a notable
influence on total health care burden. Informal care pro-
vided by family members and friends was assessed as
“non-working caregivers’ time providing medical services”,
thus representing a loss of leisure time. These costs were
counted as the real costs of care by weighing the amount
of care with the usual payment of formal care; thereby,
informal care costs were attributed to the direct costs
[12]. Within the analyzed patient cohort, 89% of DMD
and 47% of BMD patients received part- or fulltime care
by another person. Parents provided the major part of
total care time in DMD (mean 93%). In contrast, in BMD
care time was split among parents (51%) and the patients’
partners (41%). Furthermore, siblings assisted in 4%/5%
(DMD/BMD) and other relatives in 3%/11% (DMD/BMD)
of total care time. Thus, 91% of DMD patients lived to-
gether with their parents/families compared to 65% of
BMD patients. DMD relatives’ total care efforts in
hours per day were higher than those of BMD relatives
(mean h/d DMD 9.4, SD: 10.9; mean h/d BMD 2.7, SD:
6.5) with a notable increase in more severe clinical stages.
Besides the mere care time, patients needed further
Figure 1 Consumption of resources of direct medical services by dystrophinopathy patients. DMD patients showed higher utilization of
direct medical services compared to BMD patients (percentage rounded).
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ganizational tasks, mean h/d 1.41 in DMD, and h/d 0.25
in BMD (data not shown).
The mean annual costs of informal care and organiza-
tional activities were nearly three times higher in DMD
than in BMD (DMD € 21,279; BMD € 7,636; Tables 4
and 5). Costs of care for DMD patients increased with the
severity of the clinical phenotype, whereas costs in BMD
decreased from stage I to III and peaked in stage IV.
When adding care efforts of working parents on top,
total informal care costs were estimated even higher
(€ 33,402/year in DMD, € 9,224/year in BMD).
Total mean annual non-medical direct costs added up
to € 30,884 in DMD and to € 12,471 in BMD. Adding
total medical and non-medical costs, total direct mean
annual COI of DMD was estimated at € 50,230 and
significantly higher than in BMD (€ 17,611; p < 0.001;
Tables 4 and 5). In summary, our results show clear-cut
differences between the consumption of resources of dir-
ect medical and non-medical services and emerging costs
not only between DMD and BMD patients, but also be-
tween the different stages within both diseases, showing
higher costs along with disease progression.
Estimation of indirect costs caused by patients and parents
The indirect costs in DMD and BMD primarily originate
from the loss of working capacity due to the disease, andresult in lost working time and overall loss of productivity.
Our study differentiated between the lost working time of
the patient (see section a) and of his parents (or care-
givers) who often had to quit or reduce their employment
due to their son’s disease (see section b).
a) Estimation of indirect costs caused by patients
Within the BMD cohort, the number of patients with
access to higher education, mainly university studies
and completed professional education, was consider-
ably higher when compared to DMD. The percentage
of non-workers was higher in DMD than in BMD (49% vs.
32%) whereas the percentage of patients who had quit
their employment in the past was the same in DMD and
BMD (12%). Actively working DMD patients (employed
or self-employed) were between 18 and 42 years old,
whereas working BMD patients ranged from 19 and
59 years of age. DMD patients stopped working or re-
duced working hours only when they reached more severe
clinical stages (50% in stage IV), while 63% of BMD pa-
tients already had a cut-off in stage II. DMD and BMD
patients reduced working time by mean 16.6 hours/week.
The majority of patients (BMD 69%; DMD 82%) felt
handicapped in their career, leading to lower income
due to physical impairment as stated by 8% of DMD
and 35% of BMD patients (data not shown). Overall,
DMD patients’ salaries were notably lower than those




I II III IV V
Outpatient medical costs 457 (0-4,644) 1% 279 (0-3,046) 393 (0-4,644) 701 (0-2,973) 552 (0-4,356) 523 (0-2,495)
Inpatient medical costs 1,613 (0-131,454) 2% 585 (0-18,736) 804 (0-20,188) - 1,540 (0-35,525) 6,673 (0-131,454)
Rehabilitation program costs (in-/outpatient) 1,130 (0-30,053) 1% - 427 (0-17,017) 2,780 (0-15,290) 2,086 (0-30,053) 954 (0-15,290)
Drug treatment costs 330 (0-5,530) <1% 172 (0-967) 373 (0-3,837) 344 (0-746) 319 (0-5,530) 550 (0-5,122)
Costs of rehabilitation services
(e.g. physiotherapy)
4,732 (0-31,974) 6% 2,693 (0-10,658) 4,042 (0-31,974) 5,204 (0-18,097) 5,817 (0-24,657) 6,478 (0-26,839)
Costs of medical aids 10,209 (0-103,977) 13% 488 (0-4,368) 1,584 (0-11,450) 2,474 (1,285-4,805) 11,153 (0-82,673) 51,019 (1,342-103,977)
Costs of respiratory management 875 (0-12,087) 1% 3 (0-34) 6 (0-34) 163 (0-1,791) 1,522 (0-12,087) 2,771 (0-6,779)
Total direct medical costs 19,346 25% 4,220 7,629 11,666 22,989 68,968
Costs for the housing situation 4,043 (0-238,800) 5% 55 (0-1,536) 83 (0-2,280) 1,064 (0-6,900) 5,860 (0-192,000) 17,112 (0-238,800)
Costs for personal assistance for school and
work attendance
883 (0-28,800) 1% - 931 (0-15,000) 1,980 (0-9,600) 1,481 (0-28,800) -
Travel expenses 1,102 (0-17,376) 1% 358 (0-1,479) 741 (0-5,434) 1,814 (108-7,264) 1,714 (0-17,376) 915 (0-3,950)
Advocate support costs 27 (0-8,333) <1% 1 (0-33) 118 (0-8,333) 0 (0-89) 0 (0-1,623) 0 (0-59)
Investments in house adaptions 3,059 (0-93,636) 4% 2,826 (0-66,667) 0 (0-30,507) 2,239 (0-12,421) 8,499 (0-93,636) 0 (0-13,853)
Investments in automobile adaptions 408 (0-16,697) 1% 62 (0-2,833) 559 (0-11,605) 2,609 (0-12,028) 776 (0-16,697) 0 (0-6,941)
Other expenditures (e.g. artificial nutrition,
alternative therapies)
83 (0-12,000) <1% 41 (0-1,536) 223 (0-12,000) - 14 (0-735) 510 (0-6,720)
Informal care costs 21,279 (0-223,380) 27% 8,303 (0-77,563) 8,029 (0-62,050) 19,532 (3,103-43,435) 31,490 (0-223,380) 44,443 (0-158,848)
Total direct non-medical costs 30,884 39% 11,646 10,684 29,238 49,834 62,980
Total direct COI 50,230 64% 15,866 18,313 40,904 72,823 131,948
Indirect costs caused by patients 21,463 (0-43,740) 27% - 11,100 (11,100-11,100) - 18,734 (0-43,740) 28,529 (881-43,740)
Indirect costs caused by parents 7,220 (0-324,000) 9% 13,078 (0-324,000) 3,855 (0-24,000) 8,046 (0-18,000) 7,044 (0-45,100) 4,378 (0-12,000)
Total indirect COI 28,683 36% 13,078 14,955 8,046 25,778 32,907
Total COI 78,913 28,944 33,268 48,950 98,601 164,855
Total burden of illness of DMD consisting of total direct medical and non-medical costs and indirect costs was calculated per-patient in € per year while taking disease progression into account. Because of rounding,


















I II III IV V
Outpatient medical costs 366 (0-5,618) 1% 438 (0-5,618) 365 (0-2,901) 89 (0-256) 290 (0-1,066) -
Inpatient medical costs 1,186 (0-56,053) 3% 256 (0-10,767) 678 (0-18,169) - 8,837 (0-56,053) -
Rehabilitation program costs
(in-/outpatient)
375 (0-22,711) 1% 414 (0-16,977) 471 (0-22,711) - - -
Drug treatment costs 139 (0-2,452) <1% 55 (0-835) 112 (0-1-162) 286 (0-1,788) 519 (0-2,452) -
Costs of rehabilitation services
(e.g. physiotherapy)
2,249 (0-30,276) 6% 1,252 (0-9,332) 1,988 (0-23,405) 2,404 (0-14,643) 7,744 (0-30,276) -
Costs of medical aids 742 (0-17,453) 2% 55 (0-894) 658 (0-8,571) 3,611 (0-17,453) 1,725 (164-3,098) -
Costs of respiratory management 83 (0-1,281) <1% 0 (0-15) 132 (0-1,281) 5 (0-38) 234 (0-779) -
Total direct medical costs 5,140 13% 2,470 4,404 6,395 19,349 -
Costs for the housing situation 2,182 (0-126,000) 6% 190 (0-7,200) 161 (0-5,400) 300 (0-1,920) 23,933 (0-126,000) -
Costs for personal assistance for school
and work attendance
- - - - - - -
Travel expenses 1,034 (0-14,432) 3% 722 (19-3,752) 925 (0-14,432) 1,539 (0-3,621) 2,215 (377-8,144) -
Advocate support costs 1 (0-50) <1% 1 (0-40) 0 (0-27) - 7 (0-50) -
Investments in house adaptions 870 (0-26,750) 2% 192 (0-3,000) 1,118 (0-12,583) 4,369 (0-26,750) 0 (0-3,929) -
Investments in automobile adaptions 719 (0-42,210 2% - 482 (0-5,000) 7,626 (0-42,210) 0 (0-3,229) -
Other expenditures (e.g. artificial nutrition,
alternative therapies)
29 (0-2,400) <1% 21 (0-888) 44 (0-2,400) - - -
Informal care costs 7,636 (0-148,920) 20% 5,523 (0-77,562) 4,643 (0-31,025) 3,435 (0-10,859) 33,867 (0-148,920) -
Total direct non-medical costs 12,471 32% 6,649 7,373 17,269 60,022 -
Total direct COI 17,611 45% 9,119 11,777 23,664 79,371 -
Indirect costs caused by patients 18,922 (0-67,014) 48% 18,397 (0-52,756) 18,147 (0-44,394) 7,692 (0-40,500) 29,108 (0-67,014) -
Indirect costs caused by parents 2,527 (0-33,039) 6% 2,767 (0-33,039) 2,415 0-18,173) 2,105 (0-4,210) - -
Total indirect COI 21,449 55% 21,164 20,562 9,797 29,108 -
Total COI 39,060 30,283 32,339 33,461 108,479 -
Total burden of illness of BMD consisting of total direct medical and non-medical costs and indirect costs was calculated per-patient in € per year while taking disease progression into account. Because of rounding,
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ing the educational level of DMD and BMD patients
(DMD: € 11,405; BMD: € 35,871 per year; Table 3).
Based on this data, total annual indirect COI of DMD
was estimated at € 21,463 vs. € 18,922 in BMD; in both
conditions, the total annual indirect COI was highest in
the last stage of the disease (BMD stage IV, DMD stage
V) with a brief decline in stage III (Tables 4 and 5).
b) Estimation of indirect costs caused by parents
Nearly two third of the DMD parents were employed or
self-employed (BMD 78%). 29% quit their employment
to be able to care for their son. 38% of actively working
parents reduced their working hours by mean 15 hours/
week. In contrast, only 4% of BMD parents quit their
job and 12% of actively working parents reduced work-
ing time by mean 10 hours/week. DMD parents quit or
reduced their employment mainly when their sons
reached stage II; most BMD patients were in stage II/IV
when their parents stopped working. Moreover, in our
study population, parents missed a mean of 14.5 workingFigure 2 Subjectively care-related medical problems of parents. More
parents stated to have developed own medical problems related to their s
participation in rehabilitation programs (percentage rounded).days per year due to their son’s disease. This is in line
with the finding that many parents feel limited in pursu-
ing their career (DMD: 60%; BMD: 17%) and stated to
earn less due to their son’s disease (DMD 49% vs. BMD
29%; data not shown). Parents’ gross salaries in 2013
were similar in both diseases (DMD: € 24,168; BMD: €
27,414) and decreased during the progression of the disease
(Table 3). Parents’ indirect COI due to absenteeism and
reduction of working time was estimated at € 7,220 for
DMD vs. € 2,527 for BMD in 2013 (p < 0.01; Tables 4 and 5).
In addition to a loss of working capacity in DMD and
BMD parents, more than half of the DMD parents and
23% of the BMD parents themselves developed medical
problems due to the burden of their son’s disease, leading
to further consumption of medical treatment due to par-
ents’ physical or mental problems (Figure 2). Overall,
physical and mental problems of parents and caregivers
increased with the severity of their son’s impairment. Par-
ents’ own health status not only had an important impact
on their ability to care for their son, but also on their
working capacity and hence resulting indirect costs.than half of the DMD parents and nearly one quarter of the BMD
on’s disease, leading to consumption of medical treatment and
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The patients were encouraged to complete the question-
naire by themselves; alternatively, their parents assessed
the HRQOL questionnaire. HRQOL results in BMD were
better than in DMD (p < 0.001) without relevant differ-
ences between the evaluation by patients or parents
(p > 0.05). However, DMD patients assessed their HRQOL
worse than their parents did (p < 0.05; Figure 3), especially
those patients in less advanced clinical severity stages. In
general, HRQOL decreased with disease progression with
the most prominent loss between stage II and III in DMD
and a small increase between stage II and III in BMD.
Additionally, patients’ and parents’ contentment with their
care/their son’s care was analyzed. The majority of patients
were satisfied/very satisfied with their standard of care
(DMD 77%; BMD 73%). Parents’ evaluation of content-
ment with their son’s medical care was similar (DMD 79%;
BMD 82%) whereas only 0.5% (DMD) and 3% (BMD) par-
ents claimed to be very unsatisfied (data not shown).Figure 3 Health-related quality of life of dystrophinopathy patients (s
estimated better than that of DMD patients whereas HRQOL declined with
performed using PedsQL™ Measurement Model, module for neuromusculaEstimation of total disease burden
Regarding all analyzed influencing factors of direct and
indirect costs from different perspectives of patients,
caregivers and families, considerably higher mean costs
were identified for DMD (p < 0.001). Thus, direct COI of
DMD (€ 50,230) was nearly three times higher than in
BMD (€ 17,611) showing the highest COI in the most
severe clinical stage (Tables 4 and 5). Indirect costs were
approximately 1.3 times higher for DMD (€ 28,683) when
compared to BMD (€ 21,449). In total, the mean eco-
nomic burden of DMD per year was estimated at € 78,913
versus € 39,060 in BMD. Total health care burden was
significantly higher in DMD than in BMD (p < 0.001). Re-
cently, the worldwide prevalence of DMD was described
as 4.78:100,000 males in DMD, and 1.53:100,000 males in
BMD [15]. Recent calculations of the German population
[16] estimated that about 1,900 DMD patients and 600
BMD patients may live in Germany. Altogether, this im-
plicates the annual disease burden of DMD to be € 150elf- or parent-reported). In general, HRQOL of BMD patients was
disease progression, both in DMD and BMD. HRQOL assessment was
r disorders, German version 3.0. Higher scores indicate better HRQOL.
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health care burden with an estimated € 23 million.
Discussion
Our study provides the first German analysis of the DMD
health care burden which not only assesses the impact
of disease severity and progression on disease burden
but also compares the economic burden to the clinically
milder allelic BMD disease phenotype. To date, we as-
sessed the largest German patient cohort suffering from
DMD and BMD, analyzing different cost driving factors
from diverse perspectives. All enrolled patients had a gen-
etically confirmed diagnosis of DMD or BMD resulting
in a homogenous patient cohort. Total estimated disease
burden was significantly higher for DMD (€ 78,913) when
compared to BMD (€ 39,060; p < 0.001). The total COI
showed a clear increase with disease severity as similarly
reported for different neuromuscular disorders before
[17,18]. The nation-wide annual total DMD burden of ill-
ness in Germany was 6.5 times higher than the estimated
BMD burden (€ 150 vs. 23 million).
An estimation of annual per-patient direct COI showed
nearly four times higher costs of DMD than of BMD,
resulting from a higher demand of direct medical care,
nursing services and non-medical resources. Major
identified cost drivers of direct costs were informal care
costs (DMD 27%/BMD 20% of COI), costs of medical
aids (DMD 13%/BMD 2% of COI) and costs of reha-
bilitation services (DMD/BMD 6% of COI) along with
costs for the housing situation (DMD 5%/BMD 6% of
COI). These results correspond with a recent study on
facio-scapulo-humeral muscular dystrophy (FSHD) empha-
sizing the high impact of mobility impairment, activity limi-
tation and impairment of social roles on disease burden
[19]. Thus, devices that help to maintain these abilities and
allow for continued social participation play an important
role, and might even outbalance the importance of direct
medical treatment as shown by our cost estimate. Interest-
ingly, non-medical costs such as travel expenses (e.g. due to
medical consultations and treatment) and costs for personal
assistance in DMD were higher than the mean medical
costs of drug treatment or outpatient medical consulta-
tions. Comparing our study results to a recently published
international cross-sectional study on DMD disease bur-
den [8], we estimated higher direct costs (€ 50,230 vs. US
$42,360) probably resulting from a different methodology
of cost estimation. There are several discrepancies com-
paring our results to those of previous studies, since differ-
ent national health care systems or different types of
muscular dystrophies with inhomogeneous patient co-
horts were analyzed [20,21], which do not allow a close
comparison.
Informal care costs were identified as a main cost
driving factor of disease burden in both DMD and BMD,with increasing expenses along with disease progression
(mean informal COI € 21,279 vs. 7,636). In DMD, we
found a small cost reduction from stage I to II, most
likely because the very young DMD patients in stage I
(median age 4y) as toddlers require full attendance of a
caregiver despite a mild clinical phenotype. The high
standard deviations for care time display the wide range
of responses (0.5 – 24 hours per day) and possibly hint
at the patients’ and parents’ difficulties to estimate care
efforts. However, 66% of caring parents were working
and therefore our results may underestimate the actual
amount of informal care costs, since working parents
have been excluded from our calculation to prevent the
double counting of indirect and informal care costs. If
the care efforts of working parents would have been
incorporated, the informal care costs would have been
much higher. This highlights the enormous loss of working
capacity and productivity due to informal care required for
dystrophinopathies, and in particular for DMD. Recently
published data confirmed these findings by showing that
indirect costs of neuromuscular diseases - calculated as a
loss of family income - are directly influenced by the level
of informal care needed by the patients [21]. In contrast,
another recent analysis showed multiple times higher in-
direct costs compared to ours by using the human capital
approach [8], whereas we calculated indirect costs with
the actual wage of patients and parents. Therefore, our
results might be more precise and lower.
However, we did not only assess the reduced productiv-
ity, but additionally analyzed parents’ medical problems
obtaining further information on the duration and cause of
absenteeism from work. Parental medical problems based
on their son’s disease and related care were twice as fre-
quent in DMD than in BMD. Orthopedic and psychiatric
disorders were quite frequent with a higher ratio of psy-
chiatric disorders in BMD parents than in DMD parents.
In contrast, more than half of the DMD parents com-
plained of sleep disorders compared to 31% of the BMD
parents, which may hint at still unrecognized psychiatric
diseases in DMD parents. Nevertheless the age-matched
prevalence of these medical problems within the general
population still has to be analyzed before we can assume a
causal relation between the parents’ medical problems and
their son’s disease burden. However, the parents’ own
medical problems increased along with the disease pro-
gression of their son, which is in line with the correlation
between patients’ disease burden and the general disease
severity.
Furthermore, we analyzed indirect costs due to patients’
own loss of productivity - an enormous cost factor which
has not been previously analyzed for DMD and BMD
patients - which was three times higher than indirect costs
caused by parents and caregivers in DMD patients, and
even 7.5 times higher in BMD. Thus, our results show
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costs caused 36% of total burden of illness, in BMD, the
percentage was even higher (55% of total COI) due to the
higher education and employment rate reflecting a slower
disease progression and resulting in a higher gross salary
per year compared to DMD patients. We assumed that
working life starts at age 20 years and calculated a potential
salary for each non-working DMD and BMD patient over
20 years. Due to the low median age of DMD patients
(11 y), 86% of DMD patients did not cause any indirect
costs. On the contrary, indirect costs caused by parents
were notably higher for DMD than for BMD because of
the reduced autonomy of DMD patients. Real-life parents’
indirect costs may be even higher than we estimated since
only the productivity loss of one caregiver was taken into
account. Differences between patients’ and parents’ indirect
costs can be explained by our methodology. To prevent an
overestimation of parents’ loss of productivity due to quit-
ting work, we only included parents who stopped working
in 2013 whereas for patients all lost working days even be-
fore 2013 were included, assuming that their employment
status was directly illness-related. Compared to the general
German population, mean gross salaries of BMD/DMD
patients and parents were lower (mean of total German
population € 41.388 in 2013; [22]) and the percentage of
non-working patients and parents was notably higher
(mean of total German population 5.2%; [23]), illustrating
the limitations in working life of both DMD and BMD
patients and parents.
A possible underestimation of the burden of illness by
using minimum prices may be a weakness of our study,
since it is not possible to identify the exact incurred
costs without using data from health insurances. Add-
itionally, patients and parents were asked to complete
questions concerning the consumption of resources for
a defined period in the past, whereas recall bias may
have led to errors. Another limitation of our study may
be a possible selection bias by patient recruitment with
help of the German DMD/BMD patient registry, since
patients and families voluntarily participating in the DMD
patient registry may represent the more compliant and
motivated patient cohort in general. The main aim of the
DMD patient registry is to facilitate the planning of clin-
ical trials and to enhance patient recruitment into these
trials; therefore, older patients in more severe clinical
stages may be underrepresented since they do not repre-
sent the target group usually participating in clinical trials,
which may also lead to cost underestimation. Finally, since
BMD displays a more variable clinical course and a milder
phenotype than DMD, patients may face difficulties in
specifying their clinical severity stage which may result in
a lower mean age in stage III compared to stage II.
Regarding patients’ self-rated HRQOL, we identified a
decrease of quality of live with increasing clinical severity.Surprisingly, DMD patients assessed their own HRQOL
worse than their parents did. Recently, differences in
self- and parent-reported HRQOL in DMD were described
mainly in non-observable dimensions like worries/eva-
luation of familial problems and communication [24]. In
contrast, BMD’s HRQOL was similarly reported by patients
and parents, possibly due to the more mature age and
thereby advanced ability to talk about worries and impair-
ments. An advantage of our study is the use of a disease-
specific measurement tool and the assessment of both
patients’ and parents’ perspectives, which gives a more pre-
cise picture of HRQOL in dystrophinopathy patients.
Overall, our analysis of the DMD and BMD health
care burden identified indirect costs, informal care costs
and costs of medical aids and rehabilitation services
as the most important cost drivers. In DMD, the socio-
economic burden is manifold higher than in BMD, in-
creasing with disease progression and severity in both
DMD and BMD, thus leading to a similar burden of DMD
and BMD in the highest clinical severity stages.
Novel curative therapeutic strategies are currently deve-
loped which aim at the correction of the genetic defect and
thereby restoring muscle protein function to slow down
disease progression or to result in a milder clinical pheno-
type [25]. Pharmaceutical and clinical development of these
promising therapies are costly and once approved they may
add eminent costs to health care budgets. Nevertheless, our
results suggest that stopping DMD and BMD disease pro-
gression at an early stage or modifying the severity of DMD
into a milder BMD-like phenotype is likely to reduce total
disease burden along with considerably lower costs and
improvement of patients’ quality of life.
Conclusion
In conclusion, early assessments of economic aspects
and total disease burden represent the first analytical
steps towards a systematic health economic assessment
of dystrophinopathies in the light of rising innovative
therapeutic approaches. In this context, our study adds
to the validity of estimation with its comprehensive ap-
proach and its execution within a normal care environ-
ment. With emerging therapeutic strategies aiming at
dystrophin restoration and improved muscular function,
along with a milder clinical phenotype, our results show
that it is not only necessary for the patients, but also eco-
nomically justified to explore new therapies that modify
the clinical severity or slow down the progression of
the disease. This would lower the total economic disease
burden to a high extent and improve patients’ HRQOL.
Thus, our results may speed up payer negotiations re-
garding pricing and reimbursement and contribute to the
facilitation of an efficient translation of innovations from
clinical research over marketing authorization to patient
access to a reimbursed therapy.
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